When a disorder affects only a few people around the world, companies see little incentive to find out what could treat it. Increasingly, advocacy networks are funding and promoting their own research
Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company,
Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of.